Evidence map›Paper›PMID 38795248›Full record

ArticleInternational journal of hematology2024

WT1-guided pre-emptive therapy after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia.

Shota Arai, Takayoshi Tachibana, Akihiko Izumi, Takaaki Takeda, Yotaro Tamai, Shuku Sato, Chizuko Hashimoto, Katsumichi Fujimaki, Ryuji Ishii, Noriyuki Kabasawa and 5 more

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Trial
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Shota AraiDepartment of Hematology, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-Ku, Yokohama, 241-8515, Japan.
Takayoshi TachibanaDepartment of Hematology, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-Ku, Yokohama, 241-8515, Japan. tcbn@kcch.jp.ORCID http://orcid.org/0000-0002-7780-4459
Akihiko IzumiDepartment of Hematology, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-Ku, Yokohama, 241-8515, Japan.
Takaaki TakedaDepartment of Hematology, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-Ku, Yokohama, 241-8515, Japan.
Yotaro TamaiDivision of Hematology, Shonan Kamakura General Hospital, Kamakura, Japan.
Shuku SatoDivision of Hematology, Shonan Kamakura General Hospital, Kamakura, Japan.
Chizuko HashimotoDepartment of Hematology/Oncology, Yamato Municipal Hospital, Yamato, Japan.
Katsumichi FujimakiDepartment of Hematology, Fujisawa City Hospital, Fujisawa, Japan.
Ryuji IshiiDepartment of Hematology, Japan Community Health Care Organization Sagamino Hospital, Sagamihara, Japan.
Noriyuki KabasawaDivision of Hematology, Department of Medicine, Showa University Fujigaoka Hospital, Yokohama, Japan.
Akira HirasawaDepartment of Hematology, Yokohama Rosai Hospital, Yokohama, Japan.
Yasuyuki InoueDepartment of Internal Medicine, Division of Hematology, Yokohama City Seibu Hospital, St. Marianna University School of Medicine, Yokohama, Japan.
Masatsugu TanakaDepartment of Hematology, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-Ku, Yokohama, 241-8515, Japan.
Takahiro SuzukiDepartment of Hematology, Kitasato University School of Medicine, Sagamihara, Japan.
Hideaki NakajimaDepartment of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Yokohama, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Measurable residual disease (MRD)-guided pre-emptive therapies are now widely used to prevent post-transplant hematological relapse in patients with acute myeloid leukemia (AML). This single-center retrospective study aimed to clarify the significance of pre-emptive treatment based on Wilms' tumor gene-1 mRNA (WT1) monitoring for MRD in patients with AML who underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT). Patients with AML who received chemotherapy for hematological relapse or WT1 increase after allo-HSCT were eligible for inclusion. From January 2017 to June 2022, 30 patients with a median age of 57 (16-70) years were included and stratified into two groups: 10 with WT1 increase and 20 with hematological relapse. The median times from HCT to WT1 increase or hematological relapse were 309 days (range: 48-985) or 242 days (range: 67-1116), respectively. Less intensive chemotherapy using azacitidine or cytarabine was selected for all patients with WT1 increase and 12 (60%) with hematological relapse. The 1-year overall survival and event-free survival rates for WT1 increase and hematological relapse were 70% vs. 44% (P = 0.024) and 70% vs. 29% (P = 0.029), respectively. These real-world data suggest that WT1-guided pre-emptive therapy may be superior to therapy after hematological relapse in patients with AML who have undergone allo-HSCT.

Indexed as

Hematopoietic Stem Cell TransplantationLeukemia, Myeloid, AcuteNeoplasm, ResidualTransplantation, HomologousWT1 ProteinsAdolescentAdultAgedFemaleHumansMaleMiddle AgedRetrospective StudiesYoung AdultWT1 protein, humanWT1 ProteinsAcute myeloblastic leukemiaDisease relapsePre-emptive therapyWT1

Identifiers

PMID38795248

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.